Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients?

Benzinga_recent_news03-16

The data revealed on Monday that the 400mg BID fed regimen of zovegalisib demonstrated a median progression-free survival (PFS) of 11.1 months in heavily pre-treated patients with PI3Kα-mutated, HR+/...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619462503?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/16/doctor--patient--breast-cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-03-16 23:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619462503","market":"hk","top_or_hot":-1,"title":"Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients?","media":"Benzinga_recent_news","content":"<div>\n<p>The data revealed on Monday that the 400mg BID fed regimen of zovegalisib demonstrated a median progression-free survival (PFS) of 11.1 months in heavily pre-treated patients with PI3Kα-mutated, HR+/...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51272550/relay-therapeutics-cancer-drug-hits-11-1-month-progression-free-survival-what-does-this-means-for-pretreated-breast-cancer-patients\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRelay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-16 23:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/03/51272550/relay-therapeutics-cancer-drug-hits-11-1-month-progression-free-survival-what-does-this-means-for-pretreated-breast-cancer-patients><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The data revealed on Monday that the 400mg BID fed regimen of zovegalisib demonstrated a median progression-free survival (PFS) of 11.1 months in heavily pre-treated patients with PI3Kα-mutated, HR+/...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51272550/relay-therapeutics-cancer-drug-hits-11-1-month-progression-free-survival-what-does-this-means-for-pretreated-breast-cancer-patients\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/03/51272550/relay-therapeutics-cancer-drug-hits-11-1-month-progression-free-survival-what-does-this-means-for-pretreated-breast-cancer-patients","article_id":"2619462503","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/16/doctor--patient--breast-cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51272550/relay-therapeutics-cancer-drug-hits-11-1-month-progression-free-survival-what-does-this-means-for-pretreated-breast-cancer-patients","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619462503","pubTimestamp":1773673260,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Relay Therapeutics shares rise after Phase 3 data show zovegalisib achieved 11.1-month PFS in metastatic breast cancer patients.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","BK4139":"生物科技","BK4195":"互助储蓄与抵押信贷金融服务","PFS":"Provident Financial Services Inc","SMA":"Smartstop Self Storage REIT Inc","RLAY":"Relay Therapeutics","BK4217":"自存仓储房地产信托","BK4211":"区域性银行"},"translate_title":"Relay Therapeutics的癌症药物达到11.1个月无进展生存期——这对接受过治疗的乳腺癌患者意味着什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFS":1,"RLAY":1.5,"SMA":1},"content_text":"The data revealed on Monday that the 400mg BID fed regimen of zovegalisib demonstrated a median progression-free survival (PFS) of 11.1 months in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.\nMedian PFS was 11.2 months in patients with kinase mutations (n=33) and 11.0 months in patients with non-kinase mutations (n=24).\nAdditionally, the safety profile of this regimen was consistent with previous findings from the 600mg BID fasted dose, reinforcing the drug’s potential as a treatment option.\nRelay Therapeutics has shown impressive performance over the past 12 months, with shares increasing by 195.16%.\nCurrently, the stock is trading 8.6% above its 20-day simple moving average (SMA) and 30.3% above its 100-day SMA, demonstrating strong upward momentum.\nThe RSI is at 60.72, which is considered neutral territory, indicating that the stock is neither overbought nor oversold.\nMeanwhile, MACD is at 0.5310, above its signal line at 0.4757, suggesting bullish momentum.\nThe combination of neutral RSI and bullish MACD suggests mixed momentum, indicating that while the stock is positioned well, traders should remain cautious of potential volatility.\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $17.20. Recent analyst moves include:\nBelow is the Benzinga Edge scorecard for Relay Therapeutics, highlighting its strengths and weaknesses compared to the broader market:\nThe Verdict: Relay Therapeutics’ Benzinga Edge signal reveals a strong momentum score, indicating that the stock is currently outperforming the market.\nInvestors should consider this positive momentum while also monitoring upcoming earnings and trial results for further insights.\nRLAY Price Action: Relay Therapeutics shares were down 1.45% at $10.21 at the time of publication on Monday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619462503","isCrawlerRequest":true}